Table 1. Summary of vaccine trial group allocations.
| Triala | Group | Vaccine Dose (µg) | Alum | N | Challenge Intervalb |
| U | 1 | 30 | No | 14 | 3 |
| U | 2 | 7.5 | No | 14 | 3 |
| U | 3 | 1.9 | No | 14 | 3 |
| U | 4 | Saline | No | 14 | 3 |
| A | 1 | 22.5 | Yes | 14 | 4 |
| A | 2 | 7.5 | Yes | 14 | 4 |
| A | 3 | 22.5 | No | 14 | 4 |
| A | 4 | Saline | No | 14 | 4 |
| A | 5 | 22.5 | Yes | 2 | 24 |
| A | 6 | 7.5 | Yes | 2 | 24 |
| A | 7 | 22.5 | No | 2 | 24 |
a
“U” were animals in the Unadjuvanted Vaccine Trial. “A” were animals in the Adjuvanted Vaccine Trial.
b
Challenge interval is from the second vaccination until intranasal instillation of virus.